Evidation is a two-sided platform connecting individuals and enterprises. On the consumer side, we provide value to over 4 million individuals (Achievers) across the US who are highly motivated to participate in research including testing of digital health programs. On the enterprise side, Evidation provides biopharma, med-tech, big tech, academic institutions, professional societies, and government partners the ability to: generate evidence; and design, test, and deploy programs that motivate evidence-based action.
The vast majority of an individual’s lived health experience is outside of a medical facility, and yet clinicians and researchers fly blind to this aspect of an individual.
Evidation’s network of Achievers are highly motivated to participate in managing their health. We complement their active engagement with the passive monitoring of consumer wearables and apps, at their behest and with their consent.
For Sanofi, Evidation identified 30,000 individuals with type 2 diabetes, at high-risk for the flu. We nudged this population in a variety of ways to obtain the flu vaccine, resulting in a measurable increase in vaccination rates relative to those we did not engage.
Evidation is working with J&J and Apple to improve diagnosis/treatment rates and outcomes for atrial fibrillation. We identify at-risk individuals, engage through tailored insights, and nudge to contact clinicians to get appropriate care sooner.
Our product is available in these therapeutic areas: cardiovascular, respiratory, autoimmune, central nervous system, and infectious disease. Evidation has joined forces with the American College of Cardiology in heart health, and are investing in research and toolkits to support individuals with a heart failure diagnosis.